Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 83Squamous Cell Carcinoma of Head and Neck 51Carcinoma, Non-Small-Cell Lung 30Head and Neck Neoplasms 29Colonic Neoplasms 22Neoplasm Metastasis 18Neoplasms 16Rectal Neoplasms 14Pancreatic Neoplasms 10Lung Neoplasms 10Mouth Neoplasms 8Carcinoma, Squamous Cell 8Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Oropharyngeal Neoplasms 6Carcinoma 6Solid Tumors 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Gastrointestinal Neoplasms 5Breast Neoplasms 5Tongue Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Thyroid Neoplasms 3Recurrence 3Melanoma 3Digestive System Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Renal Cell 3Carcinoma, Pancreatic Ductal 3

Interventions

Cyclophosphamide 12fludarabine phosphate 7fludarabine 7venetoclax 6blinatumomab 6Cytarabine 5Lenalidomide 4Dexamethasone 4Blood Specimen Collection 4Azacitidine 4obinutuzumab 3Rituximab 3Radiotherapy 3Melphalan 3Immunotherapy, Adoptive 3pembrolizumab 2daratumumab 2Neoadjuvant Therapy 2Idarubicin 2Chemotherapy, Adjuvant 2Capecitabine 2trastuzumab deruxtecan 1tislelizumab 1tisagenlecleucel 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1tagraxofusp 1sacituzumab govitecan 1sabatolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Cetuximab × 1 year × Clear all
NCT06358430 2026-05-20

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

M.D. Anderson Cancer Center

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡